Medimmune Limited

Boston Pharmaceuticals, Inc.

Humabs Biomed Sa

Astrazeneca Ab

Qun Du

Melissa Marie Damschroder

Partha S Chowdhury

Bret Sellman

Xiaodong Xiao

Ronald Herbst

Christine Tkaczyk

Reena Varkey

Stacey Drabic

Ping Tsui

Catherine Ettinger

Jodi Karnell

Laura Carter

Brian Michael Naiman

Davide Corti

Scott A Hammond

Michael Oberst

Andrea Minola

Yariv Mazor

Srinath Kasturirangan

Andrew Grier Buchanan

Chunning Yang

Frank Irvine Comer

Taylor Cohen

Partha Chowdhury

Melissa Damschroder

The present disclosure relates to antibody molecules that bind epidermal growth factor receptor (EGFR) and/or c-Met and conjugates containing these antibody molecules. The antibody molecules and conjugates find application in the treatment of cancer, for example.

Antibody molecules and conjugates

The present disclosure is directed to leukotoxin-binding antibodies and antigen-binding fragments thereof. The antibodies and fragments can be used, for example, to detect leukotoxin and/or in methods of treating and preventinginfections.

Antibodies directed againstleukotoxins

This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.

Antibodies specific for IL-21 and uses thereof

The present disclosure is directed to anti-antibody combinations including combinations of antibodies that bind toalpha toxin (AT) protein, clumping factor A protein (ClfA), and/or at least one leukotoxin protein. Methods of treating and preventing infections comprising administering the antibody combinations are also provided herein.

Combinations of anti-antibodies

The disclosure provides humanized anti-OX40 antibodies. Also provided are methods of making such antibodies, and methods of use, e.g., treatment of cancer.

Method of treating cancer with humanized anti-OX40 antibodies

Humanized anti-OX40 antibodies and uses thereof

Growing community of inventors

Gaithersburg, MD, United States of America

Qun Du